GleamWall
中文EN

BJDX Bluejay Diagnostics, Inc.

Surgical & Medical Instruments & Apparatus · Nasdaq · SEC CIK 1704287 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY—
TTM net income YoY-12.2%
TTM EPS YoY119.8%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—

Returns

ROE-138.1%
ROA-107.8%
ROIC (approx.)-1,839.1%
Asset turnover—

Leverage & solvency

Liabilities / assets20.6%
Debt / equity0.00x
Current ratio3.91x
Interest coverage—

Cash quality & payout

Operating cash flow / net income0.85x
Accruals ratio-16.0%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31
Income statement
Revenue——
R&D expense$3.05M$3.47M
SG&A expense$3.91M$3.69M
Operating income-$6.95M-$7.17M
Interest expense$839$823,028
Net income-$6.85M-$7.72M
EBITDA-$6.88M-$7.09M
EPS (basic)-15.25-456.75
EPS (diluted)-15.25-456.75
Weighted avg. shares (diluted)449,04345,848
Balance sheet
Cash & equivalents$5.16M$4.30M
Current assets$5.46M$4.90M
PP&E, net$1.53M$1.51M
Total assets$7.12M$6.66M
Current liabilities$1.12M$810,368
Total liabilities$1.14M$927,924
Shareholders' equity$5.98M$5.73M
Shares outstanding151,133138,503
Cash flow statement
Operating cash flow-$6.05M-$7.82M
Capital expenditure$173,735$306,783
Free cash flow-$6.23M-$8.13M
Investing cash flow-$173,735-$306,783
Financing cash flow$7.09M$10.22M
Depreciation & amortization$74,182$75,618
Stock-based compensation$6$20,094

Free plan shows the latest 2 periods; Pro shows all 6 🔒

· This company does not report gross profit in XBRL.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.